<!DOCTYPE html>
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>

    <!-- Basic Page Needs
  ================================================== -->
	<meta charset="utf-8">
	<title>Times of Neurology</title>
	<meta name="description" content="Newsletter, Neurology,Epilepsy Designed by Medeka | medekahealth.com">
	<meta name="author" content="Neurology,Epilepsy">
	
    <!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
    
    <!-- CSS
  ================================================== -->
  	<link rel="stylesheet" href="css/zerogrid.css">
	<link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/responsive.css">
	<link rel="stylesheet" href="css/responsiveslides.css" />
	
	<!--[if lt IE 8]>
       <div style=' clear: both; text-align:center; position: relative;'>
         <a href="http://windows.microsoft.com/en-US/internet-explorer/products/ie/home?ocid=ie6_countdown_bannercode">
           <img src="http://storage.ie6countdown.com/assets/100/images/banners/warning_bar_0000_us.jpg" border="0" height="42" width="820" alt="You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today." />
        </a>
      </div>
    <![endif]-->
    <!--[if lt IE 9]>
		<script src="js/html5.js"></script>
		<script src="js/css3-mediaqueries.js"></script>
	<![endif]-->
	
	<link href='./images/ton.ico' rel='icon' type='image/x-icon'/>
    <script src="js/jquery.min.js"></script>
	<script src="js/responsiveslides.js"></script>
	<script>
		$(function () {
		  $("#slider").responsiveSlides({
			auto: true,
			pager: false,
			nav: true,
			speed: 500,
			maxwidth: 962,
			namespace: "centered-btns"
		  });
		});
	</script>
	
	
</head>
<body>
<!--------------Header--------------->
<header>
	<div class="subnav">
		<div class="wrap-subnav zerogrid">
			<div class="links">
				<ul>
					<li><a href="index.html">Home</a></li>
					<li><a href="aboutus.html">About</a></li>
					<li><a href="contact.html">Contact</a></li>
				</ul>
			</div>
		</div>
	</div>
	<div class="wrap-header zerogrid">
		<div id="logo"><a href="#"><img src="./images/logo.png"/></a></div>
</header>

<nav>
	<div class="wrap-nav zerogrid">
		<div class="menu">
	<ul>
		<li><a class="current" href="SV.html">Sodium Valproate</a></li>
		<li><a href="DP.html">Clobazam</a></li>
		<li><a href="OXCB.html">Oxcarbazepine</a></li>
        <li><a href="OXCB_PM.html">Pregabalin</a></li>
        <li><a href="NN.html">Neurology News</a></li>        
	</ul>
		</div>
		
		<div class="minimenu"><div>TOPICS</div>
			<select onchange="location=this.value">
            <option value="index.html">Home</option>
				<option value="SV.html">Sodium Valproate</option>
				<option value="DP.html">Clobazam</option>
           		<option value="OXCB_HM.html">Hospital Coverage </option>     
				<option value="OXCB.html">Oxcarbazepine</option>
                <option value="OXCB_PM.html">Pregabalin</option>
                <option value="EXPO.html">Disease Perspective</option>
                <option value="NN.html">Neurology News</option>
                <option value="quiz.html">Neurology Quiz</option>
			</select>
		</div>
	</div>
</nav>

<!--------------Content--------------->
<section id="content">
	<div class="wrap-content zerogrid">
	  <div class="row">
		  <div id="main-content" class="col-2-3">
            <div class="wrap-col">
					<article>
<h2h><a href="SV.html">Sodium Valproate</a></h2h>
                    <br>
					 <ul><li><h2><a href="SVpage_1.html">Sodium valproate: A gold standard for the treament of childhood epilepsy</a></h2>
						<span class="info">by medeka healthcare on october 01, 2013</a></span></li></ul>
			  </article>
					<article>
						
					  <h11>Clinical efficacy of sodium valproate</h11>
						<p>Sodium valproate is effective in epilepsy syndromes
including West syndrome, Lennox-Gestaut syndrome,
photosensitive epilepsy, and prominent myoclonic
seizures–febrile seizures and status epilepticus. Its
efficacy is comparable to carbamazepine, phenytoin,
and phenobarbital in focal epilepsy and ethosuximide
in absence epilepsy. It has low potential for seizure
worsening when compared to other AEDs.<sup><a href="SV-IV.html">2</a></sup></p>
                      <h11b>Sodium valproate in epilepsy syndromes
typical of childhood</h11b>
                      <p>Sodium valproate is effective in rare syndromes
or seizure types such as infantile spasm, atypical
absence seizures (commonly seen in Lennox-Gastaut
syndrome), febrile seizures, myoclonic or myoclonic
astatic seizures, and nonconvulsive SE.<sup><a href="SV-IV.html">2</a></sup></p>
                      <h11b>In West syndrome</h11b>
                      <ul>
                            <li>Sodium valproate has been found to be effective
in West syndrome, both at low (20 mg/kg/
day)<sup><a href="SV-IV.html">3</a></sup> and high dosages (50–100 mg/kg/day).<sup><a href="SV-IV.html">4,5</a></sup>
A recent study also has reported that sodium
valproate was effective in 39.5% of patients with
West syndrome.<sup><a href="SV-IV.html">7</a></sup></li>
                            <li>Seizure-free rates for sodium valproate are
20–45%, but in one study 16 out of 20 (80%)
patients had total seizure control with sodium
valproate monotherapy.<sup><a href="SV-IV.html">2, 5</a></sup></li>
                            <li>Its efficacy is comparable to corticosteroids
in spasm as well as hypsarrhythmic electroencephalogram
(EEG).<sup><a href="SV-IV.html">6</a></sup></li>
                            <li> For children resistant to corticotrophin and
vigabatrin, sodium valproate is a good option for
the treatment of infantile spasm.<sup><a href="SV-IV.html">2</a></sup></li>
                          </ul>
                          
                          <h11b>In Lennox-Gastaut syndrome</h11b>
                       <ul>
                            <li>Henriksen et al. have reported that sodium
valproate monotherapy was efficacious in 18% of
patients with Lennox-Gastaut syndrome.<sup><a href="SV-IV.html">8</a></sup></li>
                            <li>Sodium valproate can be safely used in patients
who have had a liver transplant and require strict
control of hepatic function.<sup><a href="SV-IV.html">9</a></sup></li>
                            <li>The combination of sodium valproate and
lamotrigine or low dose topiramate (maximum
200 mg/day) is a good option for the treatment of
Lennox-Gastaut syndrome.<sup><a href="SV-IV.html">2</a></sup></li>  </ul>
<h11b>In other epileptic conditions</h11b>
                       <ul>
                            <li>Patients with prominent myoclonic seizures
respond well to sodium valproate monotherapy
or combination of sodium valproate and
ethosuximide.<sup><a href="SV-IV.html">10,11</a></sup></li>
                            <li>Sodium valproate has been observed to be
effective in 85% of patients with photosensitive
epilepsy.<sup><a href="SV-IV.html">12</a></sup></li>
                            <li>Sodium valproate produces cognition
enhancing effects and decreases electrographic
discharges.<sup><a href="SV-IV.html">13</a></sup></li>
                            <li>Administration of sodium valproate and
benzodiazepine is also effective in reducing
EEG discharges in cognitive epilepsies.<sup><a href="SV-IV.html">14</a></sup></li><img src="images/blog02.gif"/>
                      </ul>
                          <h11b>Sodium valproate in febrile seizures</h11b>
                       <ul>
                            <li>Mamelle et al. compared sodium valproate and
phenobarbital in the prevention of relapse of
febrile convulsions. The study findings revealed
that sodium valproate was more effective than
phenobarbital (96% <i><i>vs.</i></i> 81%).<sup><a href="SV-IV.html">15</a></sup></li>
                            <li>Sodium valproate can be preferred over
phenobarbital because of its favorable safety
profile.<sup><a href="SV-IV.html">16</a></sup></li>
                      </ul>
                          <h11b>Sodium valproate in status epilepticus</h11b>
                       <ul>
                            <li>Sodium valproate IV has several advantages when
used in the management of SE:<sup><a href="SV-IV.html">2</a></sup>
                              <ul><li>Sodium valproate IV doesn’t produce
hypotension or respiratory depression and
this may be helpful as it may avoid the need
for intubation.</li>
                            <li>Sodium valproate IV can be safely infused
over a 30-minute duration.</li>
                            <li>Sodium valproate IV achieves therapeutic
concentrations quickly.</li></ul></li>
                            <li>In a recent randomized controlled trial, sodium
valproate IV showed better efficacy in terms of
seizure termination (p=0.189) and less adverse
events (p<0.001) as compared to phenobarbital
(Figure 1).<sup><a href="SV-IV.html">17</a></sup></li>
                      </ul><img src="images/figure_03.gif"/>
                          <h11b>Sodium valproate has low potential for seizure
worsening</h11b>
                      <p>Worsening of seizures occur commonly in children.
It may occur spontaneously or may be caused due
to adverse reactions to AEDs or their overdosage.
Sodium valproate induced seizure worsening
is rare when compared to other AEDs such as
carbamazepine, phenytoin, phenobarbital,
benzodiazepines, vigabatrin, gabapentin, and
lamotrigine.<sup><a href="SV-IV.html">2</a></sup></p>
                        
			  </article>
					<ul id="pagi">
						<li><a href="SV-I.html">1</a></li>
						<li><a class="current" href="SV-II.html">2</a></li>
                        <li><a href="SV-III.html">3</a></li>
                        <li><a href="SV-IV.html">4</a></li>
					</ul>
					
		    </div>
            <p><br>
            <div class="featured">
	<div class="wrap-col">
		<div class="slider">
			<div class="rslides_container">
				<ul class="rslides" id="slider">
					<li><img src="images/slide03.jpg"/></li>
					<li><img src="images/slide15.jpg"/></li>
                  
				</ul>
			</div>
		</div>
	</div>
</div>
	    </div>
			<div id="sidebar" class="col-1-3">
				<div class="wrap-col">
                <div class="box">
					  <div class="heading">
					    <h2>Contents</h2></div>
						<div class="content">
							<div class="linklist">
							  <ul><li><a href="IM.html">Initial monotherapy with levetiracetam fails more
frequently than monotherapy with valproate or
oxcarbazepine:</a>An enlightening evidence</li>
									<li><a href="SVpage_1.html">Sodium valproate:</a>A gold standard for the treatment of
childhood epilepsy</li>
									<li><a href="SVpage_2.html">Superior efficacy of sodium valproate IV reported in</a> acute seizures and status epilepticus</li>
									<li><a href="DP.html">Clobazam: </a>An effective long-term treatment option
for Lennox-Gastaut syndrome</li>
                                    <li><a href="OXCB_HM.html">Hospital coverage:</a>Krishna Institute of Medical Sciences</li>
                                <li><a href="OXCB.html">Oxcarbazepine:</a>A valuable treatment option for
partial-onset seizures in children</li>
                                      <li><a href="OXCB_PM.html">Pregabalin and methylcobalamin combination for
neuropathic pain:</a>The Indian scenario</li>
                                <li><a href="EXPO.html">Important aspects of epilepsy management:</a>during pregnancy</li>
                                    <li><a href="NN.html">Neurology News</a></li>
                                    <li><a href="quiz.html">Neurology Quiz</a></li>
                                    
								</ul>
							</div>
						</div>
				  </div>
                  <div class="box">
						<div class="heading"><h2>News Digest</h2></div>
						<div class="content">
							<div class="posts">
								<img src="images/post01.png"/>
								<h4><a href="#">ECG should be considered
in patients with refractory
epilepsy</a></h4><br>
									<p>Analysis of electrocardiogram
(ECG) monitoring
in patients with refractory
epilepsy revealed significant differences in
heart rate between ictal and pre-ictal states,
between ictal and post-ictal states, and
between pre- and post-ictal states. Hence,
ECG might be helpful to detect serious
cardiac abnormalities in patients with
refractory epilepsy.</p><p class="sideref">J Res Med Sci. 2013;18(Suppl 1):S32–4.</p>
							</div>
							<div class="posts">
								<img src="images/post02.png"/>
								<h4><a href="#">Use of gabapentin in pregnancy is not associated with increased risk of major malformations</a></h4><br>
							<p>A prospective study of
pregnancy outcomes in
223 pregnant women who were exposed to gabapentin and 223 pregnant women who were unexposed to gabapentin reported
that gabapentin use in pregnancy was not associated with increased risk for major malformations.</p> <p class="sideref">Epilepsy Behav. 2013;26(1):109–13.</p>
							</div>
							<div class="posts">
								<img src="images/post03.png"/>
								<h4><a href="#">A portable automatic device for the detection of generalized tonicclonic seizures</a></h4>
							<p>Increased S100B protein levels in cerebrospinal fluid may be associated with the neuronal damage following central nervous infections.</p>
							<p class="sideref">Epilepsia. 2013;54(4):e58–61.</p></div>
						</div>
				  </div>
					<div class="box">
						<div class="heading">
						  <h2>Updates</h2></div>
						<div class="content"> <img src="images/updates_add01.gif"/>						  <img src="images/updates_add02.gif"/>
						</div>
					</div>
				</div>
			</div>
	  </div>
  </div>
</section>
<!--------------Footer--------------->
<footer>
	<div class="copyright">
		<p>Copyright © 2013 Medekahealth.com - All rights reserved. | Design: <a href="http://www.medekahealth.com/">MedekaHealth.com</a><a href=</p>
	</div>
</footer>

</body></html>